{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:48:06Z","timestamp":1768927686429,"version":"3.49.0"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T00:00:00Z","timestamp":1425427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,5]]},"abstract":"\n Aims<\/jats:title>\n To study the short\u2010term cardiovascular effects of the once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist taspoglutide.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We conducted a meta\u2010analysis of individual\u2010participant data from nine randomized controlled trials in the\n T\u2010E<\/jats:styled-content>\n merge programme, which assessed the efficacy and safety of taspoglutide in type 2 diabetes. Our primary outcome was a composite of death from cardiovascular disease (\n CVD<\/jats:styled-content>\n ) and acute myocardial infarction, stroke and hospitalization for unstable angina.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 7056 individuals were included in the analysis, and there were 67 primary endpoint events during 7478 person\u2010years of follow\u2010up (40 vs 27 events in the intervention vs control groups, respectively). The odds ratio for the composite endpoint among people randomized to taspoglutide was 0.94 (95% confidence interval 0.57\u20131.56), which was robust across multiple subgroups. Longer\u2010term data were not available as the development of taspoglutide was stopped because of gastrointestinal intolerance and serious hypersensitivity reactions.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The available data suggest that short\u2010term, once\u2010weekly administration of taspoglutide was not associated with an excess risk of\n CVD<\/jats:styled-content>\n , and provide insights relevant to the development of other novel once\u2010weekly incretin mimetics.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12448","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T04:37:54Z","timestamp":1423111074000},"page":"505-510","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular safety of the glucagon\u2010like peptide\u20101 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta\u2010analysis of randomized controlled trials"],"prefix":"10.1111","volume":"17","author":[{"given":"S. R. K.","family":"Seshasai","sequence":"first","affiliation":[{"name":"Cardiovascular and Cell Sciences Research Institute St George's, University of London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. L.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Cardiovascular and Cell Sciences Research Institute St George's, University of London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Petrie","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre University of Glasgow Glasgow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bengus","sequence":"additional","affiliation":[{"name":"F. Hoffman La\u2010Roche Ltd Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ekman","sequence":"additional","affiliation":[{"name":"F. Hoffman La\u2010Roche Ltd Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Roche Products Limited Welwyn Garden City UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Herz","sequence":"additional","affiliation":[{"name":"F. Hoffman La\u2010Roche Ltd Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"Buse","sequence":"additional","affiliation":[{"name":"Department of Medicine University of North Carolina School of Medicine Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. K.","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care Imperial College London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,3,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60697-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1296"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S4283"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.12.007"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1309610"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1942"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0709"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3253"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-012-0013-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20042"},{"key":"e_1_2_7_17_1","unstructured":"A study of taspoglutide in patients with inadequately controlled diabetes mellitus type 2 and cardiovascular disease.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01018173 2009"},{"key":"e_1_2_7_18_1","unstructured":"A study to compare taspoglutide and insulin glargine in insulin\u2010na\u00efve patients with type 2 diabetes mellitus inadequately controlled on metformin and sulfonylurea combination therapy.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01051011?term=ZC22565&rank=1 2010"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-10-22"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164111408937"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/215764"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-48"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12448","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:36:23Z","timestamp":1761888983000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,4]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/dom.12448"],"URL":"https:\/\/doi.org\/10.1111\/dom.12448","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,4]]}}}